Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Real-World Treatment Patterns Among Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with TP53 Mutation in the United States (US)

Rebecca Bystrom, Laura L. Fernandes, Joseph Wynne, Dianne Pulte, Eric Hansen, Andrew J. Belli, Anna Barcellos, Christina M. Zettler, Jonathon Vallejo, Kelly Norsworthy, Angelo De Claro, Catherine Lerro, Marc R Theoret, Ching-Kun Wang, Donna Rivera

Blood (2023) 142 (Supplement 1): 5189.

https://doi.org/10.1182/blood-2023-189060

Published: 2023

Journal Articles

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Matthew S. Davids, Jacob Ambrose, Enrico De Nigris, Jennifer Prescott, Siyang Leng, Mohammed Z.H. Farooqui, Shravanthi R. Gandra, Christina M. Zettler, Laura L. Fernandes, Ching-Kun Wang, Mazyar Shadman

Blood (2023) 142 (Supplement 1): 6536.

https://doi.org/10.1182/blood-2023-178727

Published: 2023

Journal Articles

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Sharlene Dong, Ankit J. Kansagra, Gurbakhash Kaur, Anna Barcellos, Andrew J. Belli, Laura L. Fernandes, Eric Hansen, Jacob Ambrose, Claire Bai, Christina M. Zettler, Ching-Kun Wang

Blood (2023) 142 (Supplement 1): 5145.

https://doi.org/10.1182/blood-2023-180263

Published: 2023

Journal Articles

Real-World Treatment Patterns and Outcomes of Patients (Pts) with Follicular Lymphoma (FL) Who Experienced Progression of Disease within 24 Months (POD24)

Muhammad Saad Hamid, Claire Bai, Chelsea Perelgut, Helena Yelovich, Christina M. Zettler, Laura L. Fernandes, Andrew J. Belli, Eric Hansen, Ching-Kun Wang

Blood (2023) 142 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2023-182064

Published: 2023

Journal Articles

Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting

Blood (2023) 142 (Supplement 1): 6538.

https://doi.org/10.1182/blood-2023-180060

Published: 2023

Journal Articles

Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy

William J Archibald, Anna Barcellos, Jacob Ambrose, Andrew J. Belli, Laura Fernandes, Eric Hansen, Ching-Kun Wang, Paul M. Barr

Blood (2022) 140 (Supplement 1): 4142–4143.

https://doi.org/10.1182/blood-2022-170596

Published: 2022

Journal Articles

Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)

Dianne Pulte, Kelly J. Norsworthy, Laura Fernandes, Bindu Kanapuru, Catherine Lerro, Fatima Rizvi, Jonathon Vallejo, Kun Wang, Joseph Wynne, Anna Barcellos, Andrew J. Belli, Eric Hansen, Thomas Gwise, Paul Kluetz, Angelo De Claro, Ching-Kun Wang, Donna Rivera

Blood (2022) 140 (Supplement 1): 5100–5102.

https://doi.org/10.1182/blood-2022-169054

Published: 2022

Journal Articles

Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data

Vishal Bhatnagar, Bindu Kanapuru, Laura Fernandes, Ting-Yu Chen, Mallorie H. Fiero, Erica Horodniceanu, Nicole Gormley, Catherine Lerro, Fatima Rizvi, Yuan-Li Shen, Felice Yang, Anna Barcellos, Andrew J. Belli, Eric Hansen, Ching-Kun Wang, Donna Rivera, Paul Kluetz

Blood (2022) 140 (Supplement 1): 7156–7157.

https://doi.org/10.1182/blood-2022-166842

Published: 2022

Journal Articles

REALM (OP-RW001): Comparing the Characteristics and Clinical Outcomes of Patients with Relapsed/Refractory Multiple Myeloma in the Real World to Patients Receiving Melflufen in the Horizon Study

Sikander Ailawadhi, Ching-Kun Wang, Andrew J. Belli, Catarina Jansson Blixt, Diana Cripps, Stojan Zavisic, Karthik Ramasamy

Blood (2021) 138 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2021-148428

Published: 2021

Journal Articles

Identification of Barriers of CAR-T Utilization in Patients with Diffuse Large B-Cell Lymphoma

Farrukh T. Awan, Andrew J. Belli, Eric Hansen, Mimi Chung, Ching-Kun Wang

Blood (2021) 138 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2021-153393

Published: 2021

Journal Articles

Frontline Venetoclax (ven) Based Combination Therapy in Older Adults with Acute Myeloid Leukemia Treated in the Real-World Setting; A Multi-Institutional Retrospective Study

Prapti A. Patel, Yazan F. Madanat, Andrew J. Belli, Eric Hansen, Heidi Foss, Molly Schulte, Ching-Kun Wang

Blood (2021) 138 (Supplement 1): 4136.

https://doi.org/10.1182/blood-2021-153186

Published: 2021

Journal Articles

Evaluation of Functional and Cytogenetic High-Risk Multiple Myeloma Using Real-World Data

Ankit Kansagra, Eric Hansen, Andrew J. Belli, Stefanie Goran, Ching-Kun Wang

Blood (2021) 138 (Supplement 1): 4093.

https://doi.org/10.1182/blood-2021-149724

Published: 2021

Journal Articles

Development of an Inclusive Risk Prognostic Index for Newly Diagnosed Multiple Myeloma

Ben A Derman, Andrew J. Belli, Ching-Kun Wang, Eric Hansen, Spencer S Langerman, Andrzej Jakubowiak, Brian C-H Chiu

Blood (2021) 138 (Supplement 1): 3789.

https://doi.org/10.1182/blood-2021-149213

Published: 2021

Journal Articles

Real-World Treatment Patterns and Outcomes of Patients with Functional High-Risk (Early Relapse) Multiple Myeloma

Andrew J. Belli, MPH, Eric Hansen, MS, Ankit Kansagra, MD, Keshava Dilwali, MS, Ching-Kun Wang, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142629

Published: 2020

NARROW

Real-World Treatment Patterns Among Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with TP53 Mutation in the United States (US)

Real-World Outcomes Among 2L+ Patients with Chronic Lymphocytic Leukemia (CLL) By Line of Therapy (LOT)

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Real-World Treatment Patterns and Outcomes of Patients (Pts) with Follicular Lymphoma (FL) Who Experienced Progression of Disease within 24 Months (POD24)

Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the Real-World (rw) Practice Setting

Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy

Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)

Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data

REALM (OP-RW001): Comparing the Characteristics and Clinical Outcomes of Patients with Relapsed/Refractory Multiple Myeloma in the Real World to Patients Receiving Melflufen in the Horizon Study

Identification of Barriers of CAR-T Utilization in Patients with Diffuse Large B-Cell Lymphoma

Frontline Venetoclax (ven) Based Combination Therapy in Older Adults with Acute Myeloid Leukemia Treated in the Real-World Setting; A Multi-Institutional Retrospective Study

Evaluation of Functional and Cytogenetic High-Risk Multiple Myeloma Using Real-World Data

Development of an Inclusive Risk Prognostic Index for Newly Diagnosed Multiple Myeloma

Real-World Treatment Patterns and Outcomes of Patients with Functional High-Risk (Early Relapse) Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only